disease interaction of diabetes mellitus type-2 with Alzheimer's disease & related dementias
Jump to navigation
Jump to search
Introduction
Interactions:
- risk of dementia is increased in patients with diabetes mellitus type-2
- metformin & SGLT2 inhibitors are associated with a lower risk of dementia than other hypoglycemic agents
- risk of dementia similar for users of SGLT2 inhibitors or dulaglutide (Trulicity)[2]
- risk of dementia within 2 years is 35% lower with SGLT-2 inhibitor use than with DPP-4 inhibitor use[3]
More general terms
References
- ↑ Sunwoo Y, Park J, Choi CY et al Risk of Dementia and Alzheimer's Disease Associated With Antidiabetics: A Bayesian Network Meta-Analysis. Am J Prev Med. 2024 May 3:S0749-3797(24)00140-5 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38705542 https://www.sciencedirect.com/science/article/abs/pii/S0749379724001405
- ↑ 2.0 2.1 Hong B, Bea S, Ko HY, Kim WJ, Cho YM, Shin JY. Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia: A Population-Based Cohort Study. Ann Intern Med. 2024 Aug 27. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39186787 https://www.acpjournals.org/doi/10.7326/M23-3220
- ↑ 3.0 3.1 Shin A, Koo BK, Lee JY, Kang EH. Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study. BMJ. 2024 Aug 28;386:e079475. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39197881 Free PMC article.